Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus

Gq 信号传导在促进糖尿病足细胞损伤中的作用

基本信息

  • 批准号:
    8183128
  • 负责人:
  • 金额:
    $ 38.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-09 至 2015-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Role of Gq signaling in promoting podocyte injury in diabetes mellitus: Diabetic nephropathy (DN) is the most common cause of end stage renal disease (ESRD) in developed countries. Accumulating evidence indicates that a reduced number of podocytes are a characteristic feature of both animals and humans with diabetic kidney disease. Because podocytes are terminally differentiated cells with little potential for proliferation, podocytes that are lost cannot be effectively replaced. In turn, sufficient loss of podocytes leads to instability of the tuft and glomerulosclerosis. While the etiology of podocyte loss in DN is complex, a large body of evidence suggests that cell surface G protein coupled receptors (GPCRs) play an important, injury promoting role in DN including receptors for angiotensin II (ANGII), thromboxanes (TP), prostaglandins (EP1) and endothelins (ETA). Indeed, these GPCRs are expressed by glomerular podocytes and several of these receptor systems have been shown to promote podocyte injury both in vitro and in vivo. A common feature of these injury-promoting GPCRs is activation of Gq a-subunits (Gq). Activation of Gq and its downstream effectors might, therefore, be a final common signaling pathway that synergizes with other signaling cascades to promote podocyte injury in DN. In this regard, we found that Gq dependent CN activation promotes podocyte apoptosis, in part, by induction of the CN responsive gene COX2. Based on these observations, we hypothesized that Gq-coupled signaling cascades are important mediators of podocyte injury in DN by promoting podocyte apoptosis. To investigate this hypothesis, 3 specific aims are proposed. In specific aim #1, we have created transgenic (TG) mice that express either a constitutively activate Gq a-subunit (GqQ>L) or a Gq inhibitor (Gqi) specifically in glomerular podocytes using an inducible promoter system. We will use GqQ>L or Gqi TG mice to determine if either activating or inhibiting Gq, respectively, specifically in glomerular podocytes modulates the severity of kidney disease in a genetic model of type 1 diabetes (Akita mice). In specific aim #2, we will determine the signaling cascades activated by Gq that promote podocyte apoptosis in an immortalized podocyte cell line as well as in vivo. Lastly, in specific aim #3, we will create mice lacking COX2 specifically in podocytes and then determine the effects of podocyte specific COX2 deletion on podocyte apoptosis and glomerular damage in Akita mice. These studies will test the utility of inhibiting Gq signaling as a potential treatment strategy in DN and the role of podocyte COX2 expression in disease pathogenesis. If successful, the results may suggest novel therapeutic strategies for treating diabetic kidney disease. PUBLIC HEALTH RELEVANCE: Diabetic kidney disease is the most common cause of end-stage renal disease the United States of America. As a result, diabetic nephropathy (DN) is a significant clinical and economic burden to the health- care system. The goal of this grant application is to determine if multiple hormonal systems implicated in the pathogenesis of DN activate a final common signaling pathway that promotes kidney damage. If the studies are successful, this signaling pathway would be an important therapeutic target for the development of drugs to prevent diabetic kidney disease.
描述(申请人提供):GQ信号在促进糖尿病足细胞损伤中的作用:在发达国家,糖尿病肾病(DN)是终末期肾病(ESRD)的最常见原因。越来越多的证据表明,足细胞数量减少是患有糖尿病肾病的动物和人类的特征。由于足细胞是终末分化的细胞,几乎没有增殖的潜力,失去的足细胞不能有效地被替代。反过来,足细胞的大量丢失会导致肾小球不稳定和肾小球硬化。虽然糖尿病肾病足细胞丢失的病因很复杂,但大量证据表明,细胞表面G蛋白偶联受体(GPCRs)在糖尿病肾病中起着重要的促损伤作用,包括血管紧张素II(AngII)、血栓素(TP)、前列腺素(EP1)和内皮素(ETA)的受体。事实上,这些GPCRs是由肾小球足细胞表达的,其中几个受体系统在体外和体内都被证明促进足细胞损伤。这些促进损伤的GPCRs的一个共同特征是激活Gqα亚单位(Gq)。因此,GQ及其下游效应器的激活可能是最终共同的信号通路,与其他信号级联协同促进糖尿病肾病足细胞损伤。在这方面,我们发现依赖GQ的CN激活促进足细胞凋亡,部分是通过诱导CN反应基因COX2来实现的。基于这些观察结果,我们推测GQ偶联信号通路是糖尿病肾病足细胞损伤的重要介导者,它通过促进足细胞的凋亡而发生损伤。为了验证这一假设,我们提出了三个具体目标。在特定的目标#1中,我们创造了转基因(TG)小鼠,使用可诱导的启动子系统在肾小球足细胞中表达结构性激活的GQα亚基(GQ&gT;L)或GQ抑制物(GQI)。我们将使用GQQ>L或GQI TG小鼠来确定在1型糖尿病遗传模型(秋田鼠)中,分别激活或抑制GQ,尤其是肾小球足细胞是否调节肾脏疾病的严重程度。在特定的目标#2中,我们将确定GQ激活的信号级联,促进永生化足细胞系中以及体内的足细胞凋亡。最后,在特定的目标#3中,我们将创建足细胞特异性缺失COX2的小鼠,然后确定足细胞特异性COX2缺失对秋田小鼠足细胞凋亡和肾小球损伤的影响。这些研究将测试抑制GQ信号作为一种潜在的治疗策略在糖尿病肾病中的作用,以及足细胞COX2表达在疾病发病机制中的作用。如果成功,这一结果可能会为治疗糖尿病肾脏疾病提供新的治疗策略。 公共卫生相关性:在美利坚合众国,糖尿病肾病是终末期肾病最常见的原因。因此,糖尿病肾病是医疗保健系统的重大临床和经济负担。这项赠款申请的目的是确定与糖尿病肾病发病机制有关的多种激素系统是否激活了促进肾脏损害的最终共同信号通路。如果研究成功,这一信号通路将成为开发预防糖尿病肾病药物的重要治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Spurney其他文献

Robert Spurney的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Spurney', 18)}}的其他基金

Promoting podocyte protective cGMP signaling in diabetic kidney disease
促进糖尿病肾病中足细胞保护性 cGMP 信号传导
  • 批准号:
    10588751
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS)
治疗局灶节段性肾小球硬化症 (FSGS) 的新方法
  • 批准号:
    10670414
  • 财政年份:
    2022
  • 资助金额:
    $ 38.65万
  • 项目类别:
A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS)
治疗局灶节段性肾小球硬化症 (FSGS) 的新方法
  • 批准号:
    10513834
  • 财政年份:
    2022
  • 资助金额:
    $ 38.65万
  • 项目类别:
Novel Targets for the Treatment of Diabetic Kidney Disease
治疗糖尿病肾病的新靶点
  • 批准号:
    9031226
  • 财政年份:
    2016
  • 资助金额:
    $ 38.65万
  • 项目类别:
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus
Gq 信号传导在促进糖尿病足细胞损伤中的作用
  • 批准号:
    8547057
  • 财政年份:
    2011
  • 资助金额:
    $ 38.65万
  • 项目类别:
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus
Gq 信号传导在促进糖尿病足细胞损伤中的作用
  • 批准号:
    8329659
  • 财政年份:
    2011
  • 资助金额:
    $ 38.65万
  • 项目类别:
Role of Gq Signaling in Promoting Podocyte Injury in Diabetes Mellitus
Gq 信号传导在促进糖尿病足细胞损伤中的作用
  • 批准号:
    8730134
  • 财政年份:
    2011
  • 资助金额:
    $ 38.65万
  • 项目类别:
Mechanisms of proteinuria induced by RhoA GTPases
RhoA GTPases 诱导蛋白尿的机制
  • 批准号:
    8196338
  • 财政年份:
    2010
  • 资助金额:
    $ 38.65万
  • 项目类别:
Mechanisms of proteinuria induced by RhoA GTPases
RhoA GTPases 诱导蛋白尿的机制
  • 批准号:
    7929949
  • 财政年份:
    2010
  • 资助金额:
    $ 38.65万
  • 项目类别:
Mechanisms of proteinuria induced by RhoA GTPases
RhoA GTPases 诱导蛋白尿的机制
  • 批准号:
    8391594
  • 财政年份:
    2010
  • 资助金额:
    $ 38.65万
  • 项目类别:

相似海外基金

Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
  • 批准号:
    493141
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
  • 批准号:
    10734120
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
  • 批准号:
    445961
  • 财政年份:
    2021
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
  • 批准号:
    19K17401
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
  • 批准号:
    411570
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
  • 批准号:
    391615
  • 财政年份:
    2018
  • 资助金额:
    $ 38.65万
  • 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
  • 批准号:
    26460229
  • 财政年份:
    2014
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
  • 批准号:
    25870715
  • 财政年份:
    2013
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8531707
  • 财政年份:
    2012
  • 资助金额:
    $ 38.65万
  • 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8397394
  • 财政年份:
    2012
  • 资助金额:
    $ 38.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了